$EYPT
EyePoint Pharmaceuticals, Inc.

2021 Q2 Form 10-Q Financial Statement

#000156459021042129 Filed on August 06, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2 2020 Q1
Revenue $9.013M $4.122M $7.490M
YoY Change 118.66% -42.83% 272.27%
Cost Of Revenue $1.929M $500.0K $980.0K
YoY Change 285.8% -29.18% 196.97%
Gross Profit $7.084M $3.620M $6.510M
YoY Change 95.69% -44.34% 287.04%
Gross Profit Margin 78.6% 87.82% 86.92%
Selling, General & Admin $11.84M $10.88M $12.49M
YoY Change 8.84% -10.07% 4.73%
% of Gross Profit 167.18% 300.58% 191.78%
Research & Development $5.605M $3.276M $4.853M
YoY Change 71.09% -17.17% 27.81%
% of Gross Profit 79.12% 90.5% 74.55%
Depreciation & Amortization $682.0K $670.0K $33.00K
YoY Change 1.79% 3.08% -25.0%
% of Gross Profit 9.63% 18.51% 0.51%
Operating Expenses $19.99M $15.27M $18.93M
YoY Change 30.89% -12.09% 13.62%
Operating Profit -$10.98M -$11.15M -$11.44M
YoY Change -1.55% 9.71% -21.89%
Interest Expense $1.376M $1.806M $1.784M
YoY Change -23.81% 12.95% 74.9%
% of Operating Profit
Other Income/Expense, Net $969.0K -$1.798M -$1.730M
YoY Change -153.89% 34.88% -62.28%
Pretax Income -$10.01M -$12.95M -$13.17M
YoY Change -22.7% 12.61% -31.55%
Income Tax
% Of Pretax Income
Net Earnings -$10.01M -$12.95M -$13.17M
YoY Change -22.7% 12.63% -31.52%
Net Earnings / Revenue -111.06% -314.17% -175.89%
Basic Earnings Per Share -$0.35
Diluted Earnings Per Share -$0.35 -$1.038M -$1.140M
COMMON SHARES
Basic Shares Outstanding 28.74M
Diluted Shares Outstanding 28.74M

Balance Sheet

Concept 2021 Q2 2020 Q2 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $127.6M $22.80M $26.30M
YoY Change 459.78% -48.42% -39.4%
Cash & Equivalents $127.6M $22.80M $26.45M
Short-Term Investments
Other Short-Term Assets $3.704M $5.900M $5.600M
YoY Change -37.22% 90.32% 211.11%
Inventory $5.381M $3.773M $3.400M
Prepaid Expenses
Receivables $15.11M $7.400M $14.40M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $151.8M $39.80M $49.70M
YoY Change 281.47% -32.05% 2.75%
LONG-TERM ASSETS
Property, Plant & Equipment $2.868M $3.300M $3.400M
YoY Change -13.09% 691.37% 700.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $150.0K $200.0K $200.0K
YoY Change -25.0% 0.0% 0.0%
Total Long-Term Assets $27.00M $29.90M $30.60M
YoY Change -9.71% -8.72% -8.61%
TOTAL ASSETS
Total Short-Term Assets $151.8M $39.80M $49.70M
Total Long-Term Assets $27.00M $29.90M $30.60M
Total Assets $178.8M $69.70M $80.30M
YoY Change 156.56% -23.68% -1.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.421M $3.900M $5.200M
YoY Change 39.0% -35.71% -17.7%
Accrued Expenses $9.114M $5.131M $5.100M
YoY Change 77.63% 21.76% 74.42%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $95.00K $100.0K $0.00
YoY Change -5.0%
Total Short-Term Liabilities $16.25M $9.586M $10.30M
YoY Change 69.52% -10.59% -58.23%
LONG-TERM LIABILITIES
Long-Term Debt $36.27M $50.26M $47.80M
YoY Change -27.83% 8.67% 49.6%
Other Long-Term Liabilities $19.44M $3.026M $5.800M
YoY Change 542.37% 0.87% 176.19%
Total Long-Term Liabilities $55.71M $53.29M $53.60M
YoY Change 4.55% 8.19% 57.41%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.25M $9.586M $10.30M
Total Long-Term Liabilities $55.71M $53.29M $53.60M
Total Liabilities $71.96M $65.50M $63.80M
YoY Change 9.86% 3.77% 2.94%
SHAREHOLDERS EQUITY
Retained Earnings -$491.4M
YoY Change 11.88%
Common Stock $494.8M
YoY Change 6.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $106.9M $4.194M $16.47M
YoY Change
Total Liabilities & Shareholders Equity $178.8M $69.69M $80.30M
YoY Change 156.62% -23.7% -1.9%

Cashflow Statement

Concept 2021 Q2 2020 Q2 2020 Q1
OPERATING ACTIVITIES
Net Income -$10.01M -$12.95M -$13.17M
YoY Change -22.7% 12.63% -31.52%
Depreciation, Depletion And Amortization $682.0K $670.0K $33.00K
YoY Change 1.79% 3.08% -25.0%
Cash From Operating Activities -$10.54M -$5.120M -$16.35M
YoY Change 105.9% -70.08% 22.58%
INVESTING ACTIVITIES
Capital Expenditures -$25.00K -$20.00K $16.00K
YoY Change 25.0% -33.33% -91.21%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$25.00K -$20.00K -$16.00K
YoY Change 25.0% -33.33% -91.21%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $20.29M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -382.0K 1.660M 20.45M
YoY Change -123.01% -90.74% 75.74%
NET CHANGE
Cash From Operating Activities -10.54M -5.120M -16.35M
Cash From Investing Activities -25.00K -20.00K -16.00K
Cash From Financing Activities -382.0K 1.660M 20.45M
Net Change In Cash -10.95M -3.480M 4.085M
YoY Change 214.63% -546.15% -317.06%
FREE CASH FLOW
Cash From Operating Activities -$10.54M -$5.120M -$16.35M
Capital Expenditures -$25.00K -$20.00K $16.00K
Free Cash Flow -$10.52M -$5.100M -$16.36M
YoY Change 106.22% -70.14% 21.05%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16336000
CY2021Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent
CY2021Q2 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent
CY2020Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent
CY2021Q2 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesNoncurrent
CY2020Q4 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesNoncurrent
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Net Income Loss
NetIncomeLoss
-26124000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
16474000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-12950000
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-71000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
735000
eypt Cost Of Sales Excluding Amortization Of Acquired Intangible Assets
CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets
3319000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11084000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12318000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
2065000
us-gaap Net Income Loss
NetIncomeLoss
-22290000
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
5943000
CY2020Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
41883000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
4188000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-10010000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-12000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1180000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
106865000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
8330000
us-gaap Net Income Loss
NetIncomeLoss
-26124000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
19990000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
187000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-90000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1895000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
4188000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
18541000
us-gaap Net Income Loss
NetIncomeLoss
-22290000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
108403000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
173000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-140000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2168000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
106865000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1230000
us-gaap Depreciation
Depreciation
88000
eypt Amortization Of Debt Discount
AmortizationOfDebtDiscount
348000
us-gaap Paid In Kind Interest
PaidInKindInterest
0
us-gaap Paid In Kind Interest
PaidInKindInterest
647000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
2065000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Share Based Compensation
ShareBasedCompensation
2168000
us-gaap Share Based Compensation
ShareBasedCompensation
1895000
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
-4472000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
43000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1635000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1354000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2342000
eypt Increase Decrease In Operating Lease Liabilities And Right Of Use Asset
IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset
-74000
eypt Increase Decrease In Operating Lease Liabilities And Right Of Use Asset
IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset
-30000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-421000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-15000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25642000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21466000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
25000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
42000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-42000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
108403000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19990000
eypt Proceeds From Paycheck Protection Program Loan
ProceedsFromPaycheckProtectionProgramLoan
0
eypt Proceeds From Paycheck Protection Program Loan
ProceedsFromPaycheckProtectionProgramLoan
2041000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
140000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
58000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
20000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
82721000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45059000
us-gaap Interest Paid Net
InterestPaidNet
2403000
eypt Non Cash Unpaid Stock Issuance Costs
NonCashUnpaidStockIssuanceCosts
65000
eypt Non Cash Unpaid Stock Issuance Costs
NonCashUnpaidStockIssuanceCosts
0
eypt Payments Forgiven Under Paycheck Protection Program Loan
PaymentsForgivenUnderPaycheckProtectionProgramLoan
2041000
eypt Payments Forgiven Under Paycheck Protection Program Loan
PaymentsForgivenUnderPaycheckProtectionProgramLoan
0
us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.<span style="font-weight:normal;margin-left:36pt;"/>Operations</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">         <span style="Background-color:#FFFFFF;color:#000000;">The accompanying condensed consolidated financial statements of EyePoint Pharmaceuticals, Inc., a Delaware corporation </span>(together with its subsidiaries, the “Company”), <span style="Background-color:#FFFFFF;color:#000000;">as of June 30, 2021 and for the three and six months ended June 30, 2021 and 2020 are unaudited. Certain information in the footnote disclosures of these financial statements has been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”). These financial statements should be read in conjunction with the Company’s audited consolidated financial statements and footnotes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. In the opinion of management, these statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2020, and include all adjustments, consisting only of normal recurring adjustments, that are necessary for the fair presentation of the Company’s financial position, results of operations, comprehensive loss and cash flows for the periods indicated. The preparation of financial statements in accordance with United States (“U.S.”) generally accepted accounting principles (“GAAP”) requires management to make assumptions and estimates that affect, among other things, (i) reported amounts of assets and liabilities; (ii) disclosure of contingent assets and liabilities at the date of the consolidated financial statements; and (iii) reported amounts of revenues and expenses during the reporting period. The results of operations for the three and six months ended June 30, 2021 are not necessarily indicative of the results that may be expected for the entire fiscal year or any future period.<br/></span><br/>         The Company is a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. The Company’s pipeline leverages its proprietary Durasert<sup style="font-size:85%;line-height:120%;vertical-align:top">®</sup> technology for extended intraocular drug delivery including EYP-1901, a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration (“wet AMD”), the leading cause of vision loss among people 50 years of age and older in the United States. The Company’s product candidate pipeline also includes YUTIQ<sup style="font-size:85%;line-height:120%;vertical-align:top">®</sup> 50, a potential twice-yearly treatment for non-infectious uveitis affecting the posterior segment of the eye, one of the leading causes of blindness. The Company also has two commercial products: YUTIQ<sup style="font-size:85%;line-height:120%;vertical-align:top">®</sup>, a once every three-year treatment for chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU<sup style="font-size:85%;line-height:120%;vertical-align:top">®</sup>, a single dose treatment for postoperative inflammation following ocular surgery<span style="Background-color:#FFFFFF;">. </span></p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Local drug delivery for treating ocular diseases is a significant challenge due to the effectiveness of the blood-eye barrier. This barrier makes it difficult for systemically-administered drugs to reach the eye in sufficient quantities to have a beneficial effect without causing unacceptable adverse side effects to other organs. The Company’s validated Durasert technology, which has already been included in four products approved for marketing by the U.S. Food and Drug Administration (“FDA”), is designed to provide consistent, sustained delivery of small molecule drugs over a period of months to years through a single intravitreal injection. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company’s lead product candidate, EYP-1901, combines a bioerodible formulation of its proprietary Durasert sustained-release technology with vorolanib, a tyrosine kinase inhibitor (“TKI”). The Company is currently evaluating EYP-1901 in a Phase 1 clinical trial as a potential twice-yearly sustained delivery intravitreal treatment for wet AMD. Current approved treatments for wet AMD require monthly or bi-monthly eye injections in a physician’s office, which can cause inconvenience and discomfort and often lead to reduced compliance and poor outcomes. On May 25, 2021, the Company announced the completion of the enrollment of the Phase 1 DAVIO clinical trial of EYP-1901 and expects initial data from trial in the fourth quarter of 2021. </span></p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company is also developing YUTIQ 50 as a potential twice-yearly intravitreal treatment for chronic non-infectious uveitis affecting the posterior segment of the eye. The Company has consulted with the FDA and identified a clinical pathway for a supplemental new drug application (“sNDA”) filing that the Company expects will involve a clinical trial of a small population. The Company expects to initiate the Phase 3 clinical trial for YUTIQ 50 by the end of this year.</span></p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company also has two commercial products, YUTIQ<sup style="font-size:85%;line-height:120%;vertical-align:top">®</sup> and DEXYCU<sup style="font-size:85%;line-height:120%;vertical-align:top">®</sup>, that are being sold directly in the U.S.  </span></p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">YUTIQ<sup style="font-size:85%;line-height:120%;vertical-align:top">®</sup> (fluocinolone acetonide intravitreal implant) 0.18 mg for intravitreal injection, is a non-erodible intravitreal implant containing fluocinolone acetonide (“FA”) lasting for up to 36 months and is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. This disease affects between 60,000 to 100,000 people each year in the U.S. causes approximately 30,000 new cases of blindness every year and </span></p> <p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">is </span><span style="Background-color:#FFFFFF;">the third leading cause of blindness.</span><span style="Background-color:#FFFFFF;"> YUTIQ utilizes </span><span style="Background-color:#FFFFFF;">the Company’s proprietary Durasert</span><span style="Background-color:#FFFFFF;"><sup style="font-size:85%;line-height:120%;vertical-align:top">®</sup></span><span style="Background-color:#FFFFFF;"> sustained-release drug delivery technology platform.</span></p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">DEXYCU<sup style="font-size:85%;line-height:120%;vertical-align:top">®</sup> (dexamethasone intraocular suspension) 9%, for intraocular administration, is indicated for the treatment of post-operative ocular inflammation, with the Company’s primary focus on its use immediately following cataract surgery as a single dose treatment. DEXYCU utilizes the Company’s proprietary Verisome<sup style="font-size:85%;line-height:120%;vertical-align:top">®</sup> drug-delivery technology.</span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:4.81%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also seeking to enhance its long-term growth potential by expanding EYP-1901 beyond wet AMD into diabetic retinopathy (“DR”) and retinal vein occlusion (“RVO”), both large and growing ocular disease areas. The Company also expects to potentially identify and advance additional product pipeline candidates through clinical and regulatory development. This may be accomplished through internal discovery efforts, potential research collaborations and/or in-licensing arrangements with partner molecules and potential acquisitions of additional ophthalmic products, product candidates or technologies that complement the Company’s current product portfolio.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Effects of the COVID-19 Coronavirus Pandemic<span style="Background-color:#FFFFFF;"> </span></p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.76%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ongoing COVID-19 coronavirus pandemic<span style="Background-color:#FFFFFF;"> (the “Pandemic”)</span> has had a material and adverse impact on the Company’s business, including as a result of measures that the Company, other businesses, and governments have taken and will possibly continue to take. This includes a significant impact on cash flows from expected revenues due to the closure of ambulatory surgery centers for DEXYCU and a significant reduction in physician office visits impacting YUTIQ in 2020. The ongoing Pandemic continued to have an adverse impact on the Company’s revenues, financial condition and cash flows in the first quarter and second quarter of 2021. Further, the future progression of the Pandemic and its effects on the Company’s business and operations are uncertain at this time. Depending on the future developments that are uncertain and difficult to predict, including new information that may emerge concerning the Pandemic, the Company’s revenues, financial condition and cash flows may be adversely affected in the future as well. The Company is continuously monitoring the Pandemic and its potential effect on the Company’s financial position, results of operations and cash flows. This uncertainty could have an impact in future periods on certain estimates used in the preparation of the Company’s periodic financial results, including reserves for variable consideration related to product sales, realizability of certain receivables, assessment for excess or obsolete inventory, and impairment of long-lived assets. <span style="Background-color:#FFFFFF;">Uncertainty around the extent and duration of the Pandemic, and any future related financial impact cannot be reasonably estimated at this time.</span></p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity</p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.81%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had cash and cash equivalents of $127.6<span style="font-size:12pt;color:#000000;"> </span>million at June 30, 2021.<span style="Background-color:#FFFFFF;"> T</span>he Company has a history of operating losses and has not had significant recurring cash inflows from revenue. The Company’s operations have been financed primarily from sales of its equity securities, issuance of debt and a combination of license fees, milestone payments, royalty income and other fees received from its collaboration partners<span style="Background-color:#FFFFFF;">.</span> In the first quarter of 2019, the Company commenced the U.S. launch of its first two commercial products, YUTIQ and DEXYCU. However, the Company has not received sufficient revenues from its product sales to fund operations and the Company does not expect revenues from its product sales to generate sufficient funding to sustain its operations in the near-term. The Company expects to continue fulfilling its funding needs through cash inflows from revenue of YUTIQ and DEXYCU product sales, licensing and research collaboration transactions, additional equity capital raises and other arrangements. The Company believes that its cash and cash equivalents of $127.6 million at June 30, 2021, coupled with expected cash inflows from its product sales will enable the Company to fund its current and planned operations for <span style="Background-color:#FFFFFF;">at least the next twelve months from the date these consolidated financial statements were issued. A</span>ctual cash requirements could differ from management’s projections due to many factors, including the continued effect of the Pandemic on the Company’s business and the medical community, <span style="Background-color:#FFFFFF;">the timing and results of the Company’s clinical trials for EYP-1901, </span>additional <span style="Background-color:#FFFFFF;">investments</span> in research and development programs, the success of <span style="Background-color:#FFFFFF;">commercialization</span> for YUTIQ and DEXYCU, the actual costs of these commercialization efforts, competing technological and market developments and the costs of any strategic acquisitions and/or development of complementary business opportunities.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recently Adopted and Recently Issued Accounting Pronouncements</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.81%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New accounting pronouncements are issued periodically by the Financial Accounting Standards Board (“FASB”) and are adopted by the Company as of the specified effective dates. Unless otherwise disclosed below, the </p> <p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company believes that recently issued and adopted pronouncements will not have a material impact on the Company’s financial position, results of operations and cash flows or do not apply to the Company’s operations.   </span></p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.81%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2021, the FASB issued ASU No. 2021-04, <span style="font-style:italic;color:#000000;">Earnings Per Share (Topic 260), Debt— Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40)</span> (“ASU 2021-04”)<span style="font-style:italic;">: Issuer’s  Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. </span>The amendments<span style="Background-color:#FFFFFF;color:#444444;font-size:17pt;font-family:Arial;"> </span>are designed to clarify an issuer’s accounting for certain modifications or exchanges of freestanding equity-classified written call options that remain equity-classified after modification or exchange. The ASU provides guidance on how an issuer would measure and recognize the effects of these transactions. The standard provides a principles-based framework to determine whether an issuer should recognize the modification or exchange as an adjustment to equity or an expense. ASU 2021-04 is effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. Early adoption is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. ASU 2021-04 will be effective for the Company in the first quarter of its fiscal year ending December 31, 2022. The Company is currently evaluating the impact the adoption of this update will have on its consolidated financial statements.</p>
eypt Number Of Products Approved
NumberOfProductsApproved
4
eypt Number Of Products
NumberOfProducts
2
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
127600000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
127600000
eypt Contract With Customer Allowance For Credit Loss Increase Decrease
ContractWithCustomerAllowanceForCreditLossIncreaseDecrease
-172000
eypt Contract With Customer Allowance For Deductions Applied And Payments Made
ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade
-3931000
CY2021Q2 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
3003000
CY2019Q4 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
2241000
eypt Contract With Customer Allowance For Credit Loss Additions
ContractWithCustomerAllowanceForCreditLossAdditions
1547000
CY2021Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3135000
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2664000
CY2021Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
153000
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
747000
CY2021Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2093000
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1926000
CY2021Q2 us-gaap Inventory Net
InventoryNet
5381000
CY2020Q4 us-gaap Inventory Net
InventoryNet
5337000
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
68322000
CY2019Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
68322000
CY2021Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
68322000
CY2020Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
68322000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
43113000
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
40653000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1230000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1230000
CY2021Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
44343000
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
23979000
CY2020Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
26439000
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
615000
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
615000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1200000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1200000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3457000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5686000
CY2021Q2 eypt Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
259000
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
616000
CY2020Q4 eypt Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
0
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
647000
CY2021Q2 eypt Accrued Sales Chargebacks Rebates And Other Revenue Reserves
AccruedSalesChargebacksRebatesAndOtherRevenueReserves
2584000
CY2020Q4 eypt Accrued Sales Chargebacks Rebates And Other Revenue Reserves
AccruedSalesChargebacksRebatesAndOtherRevenueReserves
1109000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2198000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1003000
us-gaap Operating Lease Payments
OperatingLeasePayments
442000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9114000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8445000
us-gaap Line Of Credit Facility Expiration Period
LineOfCreditFacilityExpirationPeriod
P5Y
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y9M18D
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.125
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
613000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
568000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2013000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2330000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2626000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2898000
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
213000
CY2020Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
213000
CY2020Q2 us-gaap Variable Lease Cost
VariableLeaseCost
9000
CY2021Q2 us-gaap Variable Lease Cost
VariableLeaseCost
9000
us-gaap Operating Lease Expense
OperatingLeaseExpense
427000
us-gaap Operating Lease Expense
OperatingLeaseExpense
427000
us-gaap Variable Lease Cost
VariableLeaseCost
18000
us-gaap Variable Lease Cost
VariableLeaseCost
18000
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
221000
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
215000
us-gaap Operating Lease Payments
OperatingLeasePayments
430000
eypt Number Of Finance Leases
NumberOfFinanceLeases
2
CY2021Q2 eypt Finance Lease Property And Equipment Gross
FinanceLeasePropertyAndEquipmentGross
239000
CY2020Q4 eypt Finance Lease Property And Equipment Gross
FinanceLeasePropertyAndEquipmentGross
239000
CY2021Q2 eypt Finance Lease Accumulated Amortization Property And Equipment
FinanceLeaseAccumulatedAmortizationPropertyAndEquipment
115000
CY2020Q4 eypt Finance Lease Accumulated Amortization Property And Equipment
FinanceLeaseAccumulatedAmortizationPropertyAndEquipment
52000
CY2021Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
124000
CY2020Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
187000
CY2021Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
95000
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
119000
CY2021Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
35000
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
71000
CY2021Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
48683
CY2020Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
12.33
CY2021Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
130000
CY2020Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
190000
CY2021Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
30000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
62000
CY2021Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
4000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
10000
CY2021Q2 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
4000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
10000
CY2021Q2 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
29000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
58000
CY2020Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
13000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
27000
CY2020Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
2000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
5000
CY2020Q2 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
2000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
4000
CY2020Q2 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
12000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
20000
CY2021Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M18D
CY2021Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.125
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
448000
CY2021Q2 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
65000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
849000
CY2021Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
75000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
815000
CY2021Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
0
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
830000
CY2021Q2 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
0
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
346000
CY2021Q2 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
0
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3288000
CY2021Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
140000
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
662000
CY2021Q2 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
10000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2626000
CY2021Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
130000
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
48683
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
12.33
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
48683
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
12.33
CY2021Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
12.33
CY2020Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
48683
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1180000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
735000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2168000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1895000
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
10700000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y7M20D
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2450203
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1572012

Files In Submission

Name View Source Status
0001564590-21-042129-index-headers.html Edgar Link pending
0001564590-21-042129-index.html Edgar Link pending
0001564590-21-042129.txt Edgar Link pending
0001564590-21-042129-xbrl.zip Edgar Link pending
eypt-10q_20210630.htm Edgar Link pending
eypt-10q_20210630_htm.xml Edgar Link completed
eypt-20210630.xsd Edgar Link pending
eypt-20210630_cal.xml Edgar Link unprocessable
eypt-20210630_def.xml Edgar Link unprocessable
eypt-20210630_lab.xml Edgar Link unprocessable
eypt-20210630_pre.xml Edgar Link unprocessable
eypt-ex311_7.htm Edgar Link pending
eypt-ex312_9.htm Edgar Link pending
eypt-ex321_6.htm Edgar Link pending
eypt-ex322_10.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending